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Background: The cardioprotective role of hormonal replacement therapy remains in doubt, but 
interest is increasing in the vascular effects of estrogens especially in coronary circulation.
Methods: Coronary blood ﬂ  ow (CBF) was measured in 24 postmenopausal women (age 55 ± 3 
years), whose coronary arteries appeared angiographically normal, during incremental atrial 
pacing (AP) before and 20 minutes after intracoronary administration of either 75 ng/mL 17-β 
estradiol (treated group, n = 18) or 0.9% saline (controls, n = 6).
Results: Before estrogen, no differences in the coronary vasomotor responses at AP between 
the two groups (p = NS) could be detected. After estrogen, in the treated group, at the peak 
of the second AP, the coronary artery diameter decreased by 0.17 mm (p   0.005) while the 
CBF increased by 61 mL/min (p   0.05). These changes differed signiﬁ  cantly from those 
observed at the peak of ﬁ  rst AP (p   0.001 for both cases). In contrast, in the control group 
no such changes were observed. The endothelin-1 (ET-1) levels in the coronary sinus were 
signiﬁ  cantly reduced after estrogen infusion, which was negatively correlated with the degree 
of coronary artery constriction (r = −0.40, p = 0.03) and positively correlated with the increase 
in CBF (r = 0.54, p = 0.01).
Conclusions: In postmenopausal women without coronary artery disease, the intracoronary 
estrogen infusion mediates a greater increase in CBF and is positively correlated with the reduc-
tion of the coronary sinus ET-1 levels at the peak of AP.
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Introduction
Nowadays, the beneﬁ  cial effects of estrogen replacement therapy (ERT) on cardiovas-
cular events among postmenopausal women are in doubt (Hsia et al 2000; Grady et al 
2001). Many observational studies have reported a reduced incidence of cardiovas-
cular disorders in pre-menopausal women and in post-menopausal women receiving 
replacement therapy (Stampfer et al 1991; Grodstein et al 2000). However the Heart 
and Estrogen/Progestin Replacement Study showed no beneﬁ  t after 4 years of ERT 
in women with prior coronary artery disease (Hulley et al 1998). To re-examine the 
controversy, a meticulous study of the large variety of favorable biological mechanisms 
of estrogen action is needed, including not only its beneﬁ  cial effect on the plasma 
lipids proﬁ  le but also the direct effects of estrogens on vasculature (Gilligan et al 1994; 
Reis et al 1994; Austin et al 2000; Herrington et al 2000; Kallikazaros et al 2002). 
Acute exposure to estrogens may alter vascular tone via different mechanisms, both 
genomic and nongenomic. Short-term administration of 17β-estradiol has been shown 
to improve exercise-induced myocardial ischemia in postmenopausal female patients Vascular Health and Risk Management 2008:4(3) 706
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with coronary heart disease (Rosano et al 1993, 1997). 
Estrogen reverses acetylcholine-induced vasoconstriction 
of the coronary arteries in animals and in humans, maybe 
via a possible enhancement of endothelium-derived nitrous 
oxide (NO) production (Gueta et al 1997; Sughir et al 1996). 
Furthermore, plasma endothelin-1 (ET-1) concentrations 
seem to participate in the atherogenic process and to play 
a pivotal role in the coronary syndrome. Researchers have 
shown that estrogen decreases the production or the release of 
endothelium-derived constrictor factors such as ET-1 (Jiang 
et al 1992; Polderman et al 1993; Best et al 1998).
This study aimed to assess the effects of the intracoro-
nary infusion of estrogens on coronary vasomotor responses 
during atrial pacing (AP), and to investigate any possible 
relationship with the levels of the coronary sinus ET-1 in 
postmenopausal women without coronary artery disease.
Methods
Study population
The enrolled subjects were all postmenopausal women (not 
receiving replacement therapy) aged 48 to 60 years old 
who had been referred for cardiac catheterization because 
of symptoms suggesting ischemic heart disease within the 
previous 6 months. Menopause was deﬁ  ned as the absence of 
a menstrual cycle for at least 12 months and was conﬁ  rmed 
by serum levels of 17β-estradiol  50 pg/mL. Women 
were excluded from the study if they had acute coronary 
syndrome, cardiac failure, valvular disease, uncontrolled 
hypertension, diabetes mellitus, or any other major systemic 
illness before catheterization. Women who were included in 
the study were not current smokers and had angiographically 
smooth, normal-appearing coronary arteries. From this larger 
group, 26 women fulﬁ  lling the above criteria were selected, 
randomly assigned to treated or nontreated groups, and 
constituted our study population.
The Ethics Committee of our hospital approved the study 
and all patients provided written consent after being provided 
with a detailed description of the whole procedure.
Study protocol
All medications were stopped at least ﬁ  ve drug half-lives 
before the study. Sublingual nitrates were allowed, to con-
trol any symptomatic episodes of myocardial ischemia, up 
to 8 hours before the study. Cardiac catheterizations were 
performed after overnight fasting with 5–10 mg diazepam 
PO given as premedication.
After diagnostic left-side cardiac catheterization and 
administration of 10,000 U heparin IV for anticoagulation, 
a 6F Judkins guiding catheter was advanced to the ostium 
of the left coronary artery. In 5 cases with angiographically 
rather irregular coronary arteries, an intravascular ultrasound 
study was performed, to conﬁ  rm the absence of coronary ste-
noses. A 0.014-inch Doppler wire (FloWire®; Cardiometrics 
Inc.©, Mountain View, CA, USA) was advanced through the 
guiding catheter into the proximal part of the left anterior 
descending artery in 18 women, and the left circumﬂ  ex 
artery in 8 women. The wire tip was positioned in an arte-
rial segment without branch point so that a characteristic 
and stable ﬂ  ow velocity waveform could be recorded. After 
that, a 7F multipurpose catheter was introduced into the 
coronary sinus via the left femoral vein for blood sampling, 
and its position checked by ﬂ  uoroscopy. A 5F pacing wire 
was inserted via the right femoral vein and placed into the 
right atrium. Aortic pressure, heart rate, and electrocardio-
gram (ECG) were displayed continuously. Once the cardiac 
catheterization and instrumentation was complete, a period 
of 15 minutes allowed women to relax, and hemodynamic 
parameters to stabilize. Firstly, measurements of both the 
dimension of the studied coronary artery and the average 
peak coronary blood ﬂ  ow (CBF) velocity were performed 
at pre-infusion of study medications, at a ﬁ  rst AP protocol; 
at baseline (baseline-1), during the peak of AP (peak-1), and 
at 7 minutes in the recovery period (recovery-1) (Figure 1). 
Once these measurements were complete, a 20-minute 
intracoronary infusion of 17β-estradiol (75 ng/ml) (Sigma, 
Pomezia, Italy) at a rate of 1 mL/min was administered in 
20 women, called the “treated group”. In 6 women, used as 
controls, an equivalent dose of 0.9% saline was administered 
by intracoronary infusion for 20 minutes. When infusion was 
complete, a second similar AP protocol was performed and 
the above measurements were obtained again at baseline-2, at 
peak-2, and at recovery-2. Coronary sinus levels of ET-1 and 
estradiol were evaluated before and after the end of estrogen 
or saline administration.
Quantitative coronary angiography
and calculation of ﬂ  ow
Coronary angiograms were obtained in the right oblique 
projections, to measure epicardial coronary diameters using 
hand injections of 5 mg iopromide. Measurements of coro-
nary artery dimensions were taken in the proximal artery 
0.5 cm distal to the wire tip using a computer-based edge 
detection enhancement technique, analyzed with a commer-
cially available automated coronary analysis system (DCI-S 
Automated Coronary Analysis System, Philips Medical 
System, Eindhoven, Netherlands).Vascular Health and Risk Management 2008:4(3) 707
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Average peak ﬂ  ow velocity was measured on line and 
each value was taken as the average of three cardiac cycles 
(Figure 2). A quantitative estimate of CBF was calculated from 
the Doppler ﬂ  ow velocity and quantitative angiographic data 
using the following equation: Q = 0.125 × π × D2 × APV × 0.6 
where Q is ﬂ  ow (mL/min), D is the vessel diameter (mm), and 
APV is average peak velocity (cm/sec) (Gueta et al 1997).
AP protocol
Incremental AP was started at 100 bpm, and the frequency 
of stimulation was gradually increased by 20 beats every 
1 minute for a heart rate of up to 160 bpm, which stayed 
constant for 2 minutes.
Blood sampling
Coronary sinus blood was sampled at baseline and at the end 
of the intra-coronary infusions, to measure 17 β-estradiol and 
ET-1 levels with radio-immunoassay techniques.
Statistical analysis
Values are expressed as mean ± SD. Subject characteristics 
were compared between the treated and control groups using 
the independent Student’s t-test for continuous data and x2 
analysis for categorical data. Comparisons of the evaluated 
parameters before and after estrogen or saline administration 
were performed using the paired Student’s t-test. Within 
each group, the inﬂ  uence of AP on coronary artery diameter 
and CBF was assessed using the paired Student’s t-test. The 
degree of coronary constriction was deﬁ  ned as the percentage 
decrease in coronary diameter [(Dbefore – Dafter)/Dbefore * 100]. 
The Pearson correlation coefﬁ  cient was used to detect pos-
sible signiﬁ  cant correlation between coronary vasomotor 
responses and demographic and laboratory parameters. A 
value of p   0.05 was considered statistically signiﬁ  cant.
Results
Of the 26 postmenopausal women without coronary artery 
disease studied, 2 of the treated group developed a second-
degree atrioventricular block during AP and were excluded 
from the study. The clinical characteristics (Table1) of 
treated (n = 18) and control subjects (n = 6) did not differ 
signiﬁ  cantly.
Coronary sinus 17β-estradiol
and ET-1 concentrations
At baseline, there were no signiﬁ  cant differences between 
the serum levels of 17β-estradiol presented in Table 1 and 
those found in the coronary sinus. As expected, after the 
intracoronary infusions, there was a signiﬁ  cant increase in 
the 17β-estradiol coronary sinus levels in the treated group, 
Figure 1 Schematic presentation of the study protocol indicating time-points when coronary sinus samples and recordings of coronary blood ﬂ  ow (CBF) and diameter were taken.
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equivalent to pre-menopausal levels (39 ± 12 versus 350 ± 
34 pg/ml, p   0.001) but not in the control group (39 ± 13 
versus 46 ± 12 pg/ml, p = NS). Coronary sinus ET-1 levels 
were significantly decreased after estrogen infusion by 
0.66 pmol/L (41%) in the treated group (1.60 ± 0.48 versus 
0.94 ± 0.53 pmol/L, p   0.0001), but remained unchanged 
in the control group after saline infusion (1.64 ± 0.29 versus 
1.58 ± 0.33 pmol/L, p = NS).
Coronary artery responses at the ﬁ  rst
AP protocol (before the study 
medications infusion)
None of the subjects experienced typical chest pain or showed 
signiﬁ  cant ( 1 mm) ST-segment depression during the AP pro-
tocols. In the treated group, at peak-1 of AP, the coronary diam-
eter was signiﬁ  cantly reduced by 0.45 ± 0.22 mm (p   0.005) 
while the CBF was signiﬁ  cantly increased by 24.2 ± 21 mL/min 
(p   0.05) compared with baseline-1 values (Table 2, Figure 3 
and 4, upper level). At recovery-1, the coronary diameter 
Figure 2 Representative coronary blood ﬂ  ow (CBF) of left anterior descending artery of a postmenopausal woman in the treated group at the two atrial pacing (AP) protocols 
before (upper panel) and after estrogen administration (low panel).
Abbreviations: AP, aortic pressure; ECG, electrocardiogram.
Table 1 Clinical characteristics of the study population
Parameters Treated group 
(n = 18)
Controls 
(n = 6)
p
Age (years) 55.6 ± 3.7 56.2 ± 3.2 NS
Time since menopause (years) 5.7 ± 2.8 5.4 ± 3.1 NS
Body mass index (kgr/m2) 27.2 ± 1.1 27.1 ± 1.1 NS
Ofﬁ  ce systolic blood
pressure (mmHg)
142 ± 10 141 ± 10 NS
Ofﬁ  ce diastolic blood
pressure (mmHg)
88 ± 4 89 ± 4 NS
Heart rate (bpm) 72 ± 8 72 ± 8 NS
Total cholesterol (mg/dl) 228 ± 25 230 ± 20 NS
LDL cholesterol (mg/dl) 150 ± 40 145 ± 36 NS
HDL cholesterol (mg/dl) 43 ± 14 45 ± 14 NS
Serum estradiol levels (pg/ml) 40 ± 14 38 ± 14 NS
Coronary sinus estradiol
levels (pg/ml)
39 ± 12 39 ± 13 NS
Coronary sinus ET-1
levels (mol/L)
1.60 ± 0.48 1.64 ± 0.29 NS
Abbreviations: ET-1, endothelin-1; HDL, high-density lipoprotein; LDL,
low-density lipoprotein.Vascular Health and Risk Management 2008:4(3) 709
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In the control group at peak-2, the diameter was 
signiﬁ  cantly reduced by 0.41 ± 0.18 mm (p   0.005) while 
CBF signiﬁ  cantly increased by 24.9 ± 16 mL/min (p   0.05) 
compared with baseline-2 values. Also at recovery-2 
(Figure 3 and 4, low level) the diameter remained signiﬁ  -
cantly decreased and CBF remained signiﬁ  cantly increased 
compared to baseline-2 values. The above observed changes 
at the second AP protocol in both coronary diameter and CBF 
did not differ from those observed at the ﬁ  rst AP protocol 
(p = NS for all cases).
Correlations
Before estrogen administration, the baseline-1 coronary 
sinus ET-1 levels had a positive correlation with the degree 
[(Diameterbefore – Diameterafter)/Diameterbefore * 100] of 
coronary artery constriction (r = 0.87) (p   0.0001) and a 
negative correlation with CBF at peak-1 of AP (r = −0.62) 
(p   0.005) (Figure 5). The estrogen-induced changes 
in coronary sinus ET-1 levels after peak-2 of AP were 
negatively correlated with the degree of coronary artery 
constriction (r = −0.40, p = 0.03) and positively correlated 
with CBF (r = 0.54, p = 0.01). Thus patients receiving 
estrogen had a greater reduction in ET-1 levels, less con-
striction of the coronary artery, and a greater increase in 
CBF at AP (Figure 5) than patients who did not receive 
estrogen treatment.
Discussion
The present study demonstrates that in postmenopausal 
women without coronary artery disease, intracoronary 
estrogen administration signiﬁ  cantly attenuates the coronary 
artery responses at AP. In addition, the 17β-estradiol-induced 
improvement in these responses at AP is closely related to 
changes in coronary sinus ET-1 levels. The greater reduction 
in ET-1 levels was accompanied by both less constriction of 
the artery and greater increase in CBF at the peak of AP in 
this setting.
Effects of estrogen on ﬂ  ow mediated 
dilation and endothelium
The mechanisms of the possible putative antiatherosclerotic 
effect of estrogen remain unclear, and are the subject of 
intense investigation. Apart from the beneﬁ  cial effect of estro-
gen on serum lipid proﬁ  le and oxidative stress, a favorable 
modulation of coronary vasoactivity has also been proposed 
(Gilligan et al 1994; Reis et al 1994; Collins et al 1995; Austin 
et al 2000; Alexander et al 2001; Kallikazaros et al 2002). Our 
study found that estrogen signiﬁ  cantly reduced the degree of 
Table 2 Coronary artery responses at ﬁ  rst atrial pacing proto-
col in the treated group (n = 18)
Baseline-1 Peak-1 Recovery-1
Aortic
pressure (mmHg)
145/90 155/88 142/88
Heart rate (bpm) 75 ± 5 160 ± 3* 78 ± 6
Coronary artery 
diameter (mm)
3.47 ± 0.42 3.02 ± 0.41* 3.28 ± 0.49*
Average peak
velocity (cm/sec)
27.94 ± 3.31 47.61 ± 5.00* 35.44 ± 4.98*
Coronary blood
ﬂ  ow (mL/min)
82.28 ± 30.14 106.44 ± 43.51* 89.51 ± 38.86*
Notes: *p   0.05 vs (baseline-1).
remained significantly decreased and the CBF remained 
signiﬁ  cantly increased compared to baseline-1 values.
Similarly, in the control group, at peak-1 of AP the 
coronary artery diameter was significantly reduced by 
0.42 ± 0.19 mm (p   0.005) while the CBF was signiﬁ  cantly 
increased by 23.8 ± 16 mL/min (p   0.05) compared with 
baseline-1 values (Figure 3 and 4, low level). Furthermore, 
at 7 minutes into the recovery period the diameter remained 
signiﬁ  cantly decreased, and the CBF remained signiﬁ  cantly 
increased compared to baseline-1 values. There were no sig-
niﬁ  cant differences between the treated and control group in 
the above coronary vasomotor responses, at the three phases 
of the ﬁ  rst AP protocol (p = NS for all cases).
Coronary artery responses at the second 
AP protocol (after the study medications 
infusion)
At baseline-2 in either the treated or control group, infusion 
of estradiol or saline had no signiﬁ  cant effect on epicardial 
coronary artery diameter and CBF at baseline-2 compared 
with the preceding baseline-1 measurements.
In the treated group, at peak-2 of AP, the coronary artery 
diameter was significantly reduced by 0.17 ± 0.20 mm 
(p   0.005) while CBF increased by 61 ± 32 ml/min (p   0.05) 
compared to baseline-2 values (Table 3, Figure 3 and 4, upper 
level). These changes were signiﬁ  cantly different compared 
with those observed at the ﬁ  rst AP protocol (0.17 ± 0.20 vs 
0.45 ± 0.22 mm and 61 ± 32 vs 24 ± 20 mL/min, respectively, 
p   0.0001 for both cases). At recovery-2, the diameter 
remained signiﬁ  cantly decreased and CBF remained signiﬁ  -
cantly increased compared with baseline-2 values. Again, these 
changes were signiﬁ  cantly different to those observed at the 
ﬁ  rst AP protocol (0.05 ± 0.03 vs 0.19 ± 0.14 mm and 11 ± 9.6 
vs 7 ± 6 mL/min, respectively, p   0.0005 for both cases).Vascular Health and Risk Management 2008:4(3) 710
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coronary artery constriction and signiﬁ  cantly increased the 
CBF, not only at the peak of AP but also in the recovery period 
compared to baseline. These ﬁ  ndings are in agreement with 
previous studies and support the hypothesis that estrogen may 
possess anti-ischemic effects (Rosano et al 1993, 1997). The 
observed reduction of coronary constriction and improvement 
of ﬂ  ow during the second period of AP may be due to warm 
up effect, since the two AP protocols could potentially have 
caused cardiac preconditioning. However, our control subjects 
did not show any change in the degree of AP-induced changes 
Figure 3 Plot of coronary artery diameter at baseline-1, peak-1, recovery-1, and baseline-2, peak-2, recovery-2 of the ﬁ  rst and second atrial pacing (AP) protocol, respectively. 
Upper panel: For the treated group before (solid line) and after estrogen administration (dotted line). Low panel: For the control group before (solid line) and after saline 
administration (dotted line).
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in the coronary cross-sectional area or CBF; therefore, no 
effect resulting in cardiac preconditioning was observed in 
this protocol. In addition, the two AP protocols were separated 
by at least 30 minutes, so that the recovery period was long 
enough to avoid any preconditioning effect.
The effects of AP on coronary artery diameter in previous 
studies are controversial (Quyyumi et al 1995; Vojacek et al 
1995; Nishikawa et al 1997). In our study, AP at baseline-
1 resulted in a decrease in coronary artery diameter. This 
ﬁ  nding, although it differs from the results of previous 
Figure 4 Plot of coronary blood ﬂ  ow (CBF) at baseline-1, peak-1, recovery-1 and baseline-2, peak-2, recovery-2 of the ﬁ  rst and second atrial pacing (AP) protocol, respectively. 
Upper panel: For the treated group before (solid line) and after estrogen administration (dotted line). Low panel: For the control group before (solid line) and after saline 
administration (dotted line).
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studies (Quyyumi et al 1995; Nishikawa et al 1997) could 
be explained by the differences in AP protocol, the extent 
of coronary atherosclerosis, the study population, and the 
presence of different risk factors.
Effects of estrogen on endothelin-1 levels
The above vasoactive coronary properties of estrogen 
may be mediated via promotion of the release or action 
of potentially beneﬁ  cial substances, such as nitric oxide 
(Gueta et al 1997; Rosano et al 1997; Best et al 1998) 
or via reduction of the release or action of potentially 
adverse mediators such as ET-1 (Jiang et al 1992; Lerman 
et al 1995; Lamping et al 1996; Sudhir et al 1996, 1997; 
Webb et al 2000). Researchers have reported that short-
term 17β-estradiol administration into the coronary cir-
culation decreases coronary blood ET-1 level (Webb et al 
2000). Our study conﬁ  rmed that acute administration of 
estrogen results in a signiﬁ  cant decrease in intracoronary 
ET-1 levels. Furthermore, our study is unique because we 
showed for the ﬁ  rst time that a relationship exists between 
the estrogen-induced reduction in coronary sinus ET-1 
levels and the degree of both the constriction of the coro-
nary artery and the increase in CBF at the peak of AP in 
Table 3 Coronary artery responses at second atrial pacing 
protocol in the treated group (n = 18)
Baseline-2 Pacing-2 Recovery-2
Aortic pressure 
(mmHg)
141/87 153/85 142/88
Heart rate (bpm) 77 ± 4 160 ± 4* 80 ± 5
Coronary artery
diameter (mm)
3.49 ± 0.41 3.32 ± 0.41* 3.44 ± 0.40*
Average peak
velocity (cm/sec)
28.61 ± 2.70 53.77 ± 6.55* 34.37 ± 4.02*
Coronary blood
ﬂ  ow (mL/min)
84.82 ± 28.95 145.01 ± 54.42*95.58 ± 35.01*
Notes: *p   0.005 vs baseline-2.
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Figure 5 Graphs of correlations of coronary blood ﬂ  ow (CBF) or degree of constriction, and levels of endothelin before and after estrogen infusion when atrial pacing (AP) 
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postmenopausal women without atherosclerotic coronary 
arteries. Demonstrating a possible interrelationship between 
coronary vasomotor responses at exercise, by means of AP, 
and ET-1 levels may provide important information on the 
effects of estrogen on coronary circulation in this setting. 
Carolyn Webb and colleagues (2000) reported no change 
in coronary vasomotor or ﬂ  ow responses associated with a 
decrease in ET-1 levels in estradiol alone. However, there 
are some signiﬁ  cant differences between these two studies, 
which could account for this controversy. First, our study 
demonstrated a nearly twofold decrease in ET-1 level (41%) 
compared with those observed (23%) in Webb’s study. Thus 
we can suggest that the degree of vasomotor response may 
be determined, at least partially, by the degree of decrease 
in ET-1 level. Secondly, the test used for endothelial func-
tion was different because the estrogen induced coronary 
vasomotor responses to substance P may not be so similar 
to those observed with AP. Third, the effects of estrogen 
on coronary vasomotor responses as well as the changes in 
the vasoconstrictor mediators may depend on the severity 
of the underlying coronary artery disease.
The above mentioned estrogen-induced decrease in plasma 
ET-1 levels may possibly explain some of the acute anti-
ischemic effects of estrogen. In addition, in postmenopausal 
women, long-term ERT decreased plasma ET-1 levels in the 
systematic circulation, associated with an increased NO-to-ET-
1 ratio (Polderman et al 1993; Lieberman et al 1994). Further-
more, one study reported that one month of treatment with 2 mg 
oral estradiol substantially reduced the forearm vasoconstrictor 
responses to ET-1, an effect which was lost three months later. 
Researchers have suggested that one potentially beneﬁ  cial 
vascular action of ERT is subject to tachyphylaxis (Jhund 
et al 2001). If that is true, the combination of ERT with ET-1 
antagonists may be a more suitable project in this setting.
In conclusion, intra-coronary 17β-estradiol administra-
tion affects the coronary vasomotor response favorably 
during AP in postmenopausal women without coronary 
artery disease. The improvement in both coronary artery 
constriction and CBF is closely related to estrogen-induced 
changes in the coronary sinus ET-1 levels. These ﬁ  ndings 
provide new insights on the favorable effects of estrogen 
on vascular endothelium and may strengthen the growing 
interest in its potential beneﬁ  t in postmenopausal women 
without coronary artery disease.
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